<DOC>
	<DOCNO>NCT02161952</DOCNO>
	<brief_summary>The aim study ass whether two-year treatment Pirfenidone influence necro-inflammation , fibrosis steatosis patient chronic hepatitis C .</brief_summary>
	<brief_title>Pirfenidone , Antifibrotic Antiinflammatory Drug</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Patients establish advanced liver disease cause hepatitis C virus ( HCV ) chronic infection define positive test antiHCV antibody detectable serum HCV RNA ( Amplicor HCV 2.0 polymerase chain reaction ( PCR ) assay ) . Sign inform consent form allow collection liver biopsy treatment . No antifibrotic , antiviral immunosuppressive drug least 6 month start pirfenidone therapy . No alcohol intake least 6 month Pirfenidone ( PFD ) treatment . Patients clinical contraindication hepatic biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Fibrosis , necroinflammation , hepatitis C chronic</keyword>
</DOC>